Trial Condition(s):

Macular degeneration

Evaluation of Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept

Bayer Identifier:

16526

ClinicalTrials.gov Identifier:

NCT02615496

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The study will be an observational, cross-sectional study of knowledge, understanding, and self-reported behavior among a sample of physicians and patients with recent aflibercept experience in a total of up to five European countries.

Inclusion Criteria
:
Physicians eligibility:
 -  Licensed and practicing ophthalmologist
 -  Prescribed and administered aflibercept to at least one patient in the past 6 months 
Patients eligibility:
 -  Patient has been administered aflibercept at least once within the last 6 months for any indication and is returning for a subsequent visit.
 -  Patient is aged 18 years or older.
 -  Patient is able to understand and sign the consent form and patient questionnaire.
 -  Patient can understand the native language of the country in which the study is being conducted.
 -  Patient has not participated in a clinical trial for the treatment of an aflibercept indication (e.g., wAMD, CRVO, or DME) in the past 12 months.
Exclusion Criteria
No Exclusion Criteria Available

Trial Summary

Enrollment Goal
716
Trial Dates
black-arrow
Phase
4
Could I receive a placebo?
No
Products
Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, United Kingdom

Status
Completed
 
Locations

Investigative Site

Many Locations, Germany

Status
Completed
 
Locations

Investigative Site

Many Locations, France

Status
Completed
 
Locations

Investigative Site

Many Locations, Spain

Status
Completed
 
Locations

Investigative Site

Many Locations, Italy

Status
Completed
 

Trial Design